Infectious Disease Project Organ-Based Infections: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
mNo edit summary
Line 172: Line 172:


<h4>Pericarditis, bacterial {{ID-returntotop-organ}}</h4>
<h4>Pericarditis, bacterial {{ID-returntotop-organ}}</h4>
* Bacterial pericarditis
:* '''Empiric antimicrobial therapy'''<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref><ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:::* Preferred regimen: [[Vancomycin]] 1 g IV q12h targeting trough levels of 15–20 μg/mL for 28 days {{and}} [[Ciprofloxacin]] 400 mg IV q12h for 28 days
:::* Alternative regimen (1): [[Vancomycin]] 1 g IV q12h targeting trough levels of 15–20 μg/mL for 28 days {{and}} [[Cefepime]] 2 g IV q12h for 28 days
:::* Alternative regimen (2): [[Vancomycin]] 1 g IV q12h targeting trough levels of 15–20 μg/mL for 14–42 days {{and}} [[Ceftriaxone]] 2 g IV q24h for 14–42 days
:::: Note: [[Pericardiocentesis]] must be promptly performed.  Pericardial drainage combined with effective systemic antibiotic therapy is mandatory (antistaphylococcal agent plus aminoglycoside, followed by tailored antibiotic therapy according to cultures).  Frequent irrigation of the pericardial cavity with [[urokinase]] or [[streptokinase]] may be considered.  Open surgical drainage through subxiphoid pericardiotomy is preferable.  [[Pericardiectomy]] may be required in patients with dense adhesions, loculated and thick purulent effusion, recurrence of tamponade, persistent infection, and progression to constriction.
:* Specific considerations<ref>{{Cite journal| doi = 10.1016/j.ehj.2004.02.002| issn = 0195-668X| volume = 25| issue = 7| pages = 587–610| last1 = Maisch| first1 = Bernhard| last2 = Seferović| first2 = Petar M.| last3 = Ristić| first3 = Arsen D.| last4 = Erbel| first4 = Raimund| last5 = Rienmüller| first5 = Reiner| last6 = Adler| first6 = Yehuda| last7 = Tomkowski| first7 = Witold Z.| last8 = Thiene| first8 = Gaetano| last9 = Yacoub| first9 = Magdi H.| last10 = Task Force on the Diagnosis and Management of Pricardial Diseases of the European Society of Cardiology| title = Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology| journal = European Heart Journal| date = 2004-04| pmid = 15120056}}</ref><ref>{{Cite journal| issn = 1175-3277| volume = 5| issue = 2| pages = 103–112| last1 = Pankuweit| first1 = Sabine| last2 = Ristić| first2 = Arsen D.| last3 = Seferović| first3 = Petar M.| last4 = Maisch| first4 = Bernhard| title = Bacterial pericarditis: diagnosis and management| journal = American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions| date = 2005| pmid = 15725041}}</ref><ref>{{Cite journal| issn = 1092-8464| volume = 2| issue = 4| pages = 343–350| last = Goodman| first = null| title = Purulent Pericarditis| journal = Current Treatment Options in Cardiovascular Medicine| date = 2000-08| pmid = 11096539}}</ref><ref>{{cite book | last = Cherry | first = James | title = Feigin and Cherry's textbook of pediatric infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2014 | isbn = 978-1455711772 }}</ref>
::* '''Purulent pericarditis with contiguous pneumonia'''
:::* Preferred regimen: [[Vancomycin]] 1 g IV q12h targeting trough levels of 15–20 μg/mL {{and}} ([[Ceftriaxone]] 1–2 g IV q12h {{or}} [[Cefotaxime]] 2 g IV q6–8h) {{and}} ([[Ciprofloxacin]] 400 mg IV q12h {{or}} [[Levofloxacin]] 500–750 mg IV q24h)
::* '''Purulent pericarditis with contiguous head and neck infection'''
:::* Preferred regimen: [[Imipenem]] 500 mg IV q6–8h {{or}} [[Ampicillin-Sulbactam]] 3 g IV q6h
::* '''Purulent pericarditis secondary to infective endocarditis'''
:::* Preferred regimen: [[Vancomycin]] 15–20 mg/kg IV q8–12h targeting trough levels of 15–20 μg/mL {{and}} [[Gentamicin]] 3 mg/kg/day IV q8–12h
::* '''Purulent pericarditis after cardiac surgery, pediatric'''
:::* Preferred regimen: [[Vancomycin]] 15 mg/kg IV q6h targeting trough levels of 15–20 μg/mL {{and}} ([[Ceftriaxone]] 100 mg/kg/day IV q12–24h {{or}} [[Cefotaxime]] 200–300 mg/kg/day IV q6–8h) {{and}} [[Gentamicin]] 6–7.5 mg/kg/day IV q8h
::* '''Purulent pericarditis with genitourinary infection, pediatric'''
:::* Preferred regimen: [[Vancomycin]] 15 mg/kg IV q6h targeting trough levels of 15–20 μg/mL {{and}} ([[Ceftriaxone]] 100 mg/kg/day IV q12–24h {{or}} [[Cefotaxime]] 200–300 mg/kg/day IV q6–8h) {{and}} [[Gentamicin]] 6–7.5 mg/kg/day IV q8h
::* '''Purulent pericarditis in immunocompromised host, pediatric'''
:::* Preferred regimen: [[Vancomycin]] 15 mg/kg IV q6h targeting trough levels of 15–20 μg/mL {{and}} ([[Ceftriaxone]] 100 mg/kg/day IV q12–24h {{or}} [[Cefotaxime]] 200–300 mg/kg/day IV q6–8h) {{and}} [[Gentamicin]] 6–7.5 mg/kg/day IV q8h
:* Pathogen-directed antimicrobial therapy<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
::* '''Anaerobes'''
:::* Preferred regimen: [[Clindamycin]] 600–900 mg IV q8h for 14–42 days {{or}} [[Metronidazole]] 7.5 mg/kg IV q6h for 14–42 days {{or}} [[Ampicillin-Sulbactam]] 3 g IV q6h for 14–42 days
::* '''Gram-negative bacilli'''
:::* Preferred regimen: [[Ciprofloxacin]] 400 mg IV q12h for 14–42 days {{or}} [[Levofloxacin]] 500–750 mg IV q24h for 14–42 days {{or}} [[Cefepime]] 2 g IV q12h for 14–42 days
::* '''Legionella pneumophila'''
:::* Preferred regimen: [[Ciprofloxacin]] 400 mg IV q12h for 14–42 days {{or}} [[Levofloxacin]] 500–750 mg IV q24h for 14–42 days {{or}} [[Azithromycin]] 500 mg IV q24h for 14–42 days
::* '''Mycoplasma pneumoniae'''
:::* Preferred regimen: [[Doxycycline]] 100 mg IV q12h for 14–42 days {{or}} [[Azithromycin]] 500 mg IV q24h for 14–42 days
::* '''Neisseria meningitidis'''
:::* Preferred regimen: [[Penicillin G]] 5–24 MU/day IM/IV q4–6h for 14–42 days {{or}} [[Cefotaxime]] 2 g IV q6–8h for 14–42 days {{or}} [[Ceftriaxone]] 2 g IV q24h for 14–42 days
::* '''Staphylococcus aureus, methicillin-susceptible'''
:::* Preferred regimen: [[Nafcillin]] 1–2 g IV q4h for 14–42 days {{or}} [[Oxacillin]] 1–2 g IV q4h for 14–42 days {{or}} [[Cefazolin]] 1–2 g IV q48h for 14–42 days {{or}} [[Vancomycin]] 1 g IV q12h targeting trough levels of 15–20 μg/mL for 14–42 days {{or}} [[Clindamycin]] 600–900 mg IV q8h for 14–42 days
::* '''Staphylococcus aureus, methicillin-resistant'''
:::* Preferred regimen: [[Vancomycin]] 1 g IV q12h targeting trough levels of 15–20 μg/mL for 14–42 days {{or}} [[Linezolid]] 600 mg IV q12h for 14–42 days
::* '''Streptococcus pneumoniae, penicillin-susceptible'''
:::* Preferred regimen: [[Penicillin G]] 5–24 MU/day IM/IV q4–6h for 14–42 days {{or}} [[Cefotaxime]] 2 g IV q6–8h for 14–42 days {{or}} [[Ciprofloxacin]] 400 mg IV q12h for 14–42 days {{or}} [[Levofloxacin]] 500–750 mg IV q24h for 14–42 days
::* '''Streptococcus pneumoniae, penicillin-resistant'''
:::* Preferred regimen: [[Ciprofloxacin]] 400 mg IV q12h for 14–42 days {{or}} [[Levofloxacin]] 500–750 mg IV q24h for 14–42 days {{or}} [[Vancomycin]] 1 g IV q12h targeting trough levels of 15–20 μg/mL for 14–42 days


<h4>Pericarditis, fungal {{ID-returntotop-organ}}</h4>
<h4>Pericarditis, fungal {{ID-returntotop-organ}}</h4>

Revision as of 21:04, 2 June 2015

    Mission Statement    
    Antimicrobial Agents    
    Organ-Based Infections    
    Pathogen-Based Infections    
    Gallery    

WikiDoc Infectious Disease Project — Organ-Based Infections

Cardiovascular  ●  Central Nervous System  ●  Head and Neck  ●  Eye  ●  Upper Respiratory Tract  ●  Lower Respiratory Tract  ●  Gastrointestinal and Intraabdominal  ●  Genitourinary  ●  Musculoskeletal  ●  Skin and Soft Tissues  ●  Systemic

The unnamed parameter 2= is no longer supported. Please see the documentation for {{columns-list}}.
3

Cardiovascular

Aortitis, infectious ⇧ Return to Top ⇧

Cardiovascular implantable electronic device infections ⇧ Return to Top ⇧

Endocarditis

Endocarditis, prophylaxis ⇧ Return to Top ⇧

Endocarditis, treatment ⇧ Return to Top ⇧

  • Infective endocarditis[1]
  • Culture-negative endocarditis
  • Culture-negative, native valve endocarditis
  • Culture-negative, prosthetic valve endocarditis (early, ≤ 1 year)
  • Culture-negative, prosthetic valve endocarditis (late, > 1 year)
  • Culture-negative, prosthetic valve endocarditis (early, ≤ 1 year)
  • Pathogen-directed antimicrobial therapy
  • Bartonella
  • Suspected Bartonella endocarditis
  • Documented Bartonella endocarditis
  • Enterococcus
  • Endocarditis caused by enterococcal strains susceptible to penicillin, gentamicin, and vancomycin
  • Preferred regimen : Ampicillin 12 g/24h IV q4h for 4–6 weeks OR Penicillin G 18–30 million U/24h IV either continuously or q4h for 4–6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 4–6weeks
  • Alternative regimen : Vancomycin 30 mg/kg/24h IV q12h for 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8h for 6 weeks
  • Pediatric dose: Vancomycin 40 mg/kg/24h IV q8–12h; Gentamicin 3 mg/kg/24h IV/IM q8h
  • Endocarditis caused by enterococcal strains susceptible to penicillin, streptomycin, and vancomycin and resistant to gentamicin
  • Endocarditis caused by enterococcal strains resistant to penicillin and susceptible to aminoglycoside and vancomycin
  • β-Lactamase–producing strain
  • Intrinsic penicillin resistance
  • Endocarditis caused by enterococcal strains resistant to penicillin, gentamicin, and vancomycin
  • Enterococcus faecium
  • Enterococcus faecalis
  • HACEK organisms
  • Endocarditis caused by Haemophilus, Aggregatibacter (Actinobacillus), Cardiobacterium, Eikenella corrodens, or Kingella
  • Staphylococcus
  • Native valve endocarditis caused by oxacillin-susceptible staphylococci
  • Native valve endocarditis caused by oxacillin-resistant staphylococci
  • Preferred regimen: Vancomycin 30 mg/kg/24h IV q12h for 6 weeks
  • Pediatric dose: Vancomycin 40 mg/kg/24h IV q8–12h
  • Prosthetic valve endocarditis caused by oxacillin-susceptible staphylococci
  • Prosthetic valve endocarditis caused by oxacillin-resistant staphylococci
  • Preferred regimen: Vancomycin 30 mg/kg 24 h q12h for ≥ 6 weeks AND Rifampin 900 mg/24h IV/PO q8h for ≥ 6 weeks AND Gentamicin 3 mg/kg/24h IV/IM q8–12h for 2 weeks
  • Pediatric dose: Vancomycin 40 mg/kg/24h IV q8–12h; Rifampin 20 mg/kg/24h IV/PO q8h (up to adult dose); Gentamicin 3 mg/kg/24h IV or IM q8h
  • Viridans group streptococci and Streptococcus bovis
  • Native valve endocarditis caused by highly penicillin-susceptible viridans group streptococci and Streptococcus bovis (MIC ≤ 0.12 μg/mL)
  • Preferred regimen: Penicillin G 12–18 million U/24h IV either continuously or q4–6h for 4 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 4 weeks
  • Alternative regimen (1): (Penicillin G 12–18 million U/24h IV either continuously or q4h for 2 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 2 weeks) AND Gentamicin 3 mg/kg/24h IV/IM in 1 dose for 2 weeks
  • Alternative regimen (2): Vancomycin 30 mg/kg/24h IV q12h not to exceed 2 g/24h for 4 weeks
  • Pediatric dose: Penicillin G 200,000 U/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM in 1 dose; Gentamicin 3 mg/kg/24h IV/IM in 1 dose or q8h; Vancomycin 40 mg/kg/24h IV q8–12h
  • Native valve endocarditis caused by relatively penicillin-resistant viridans group streptococci and Streptococcus bovis (MIC > 0.12 to ≤ 0.5 μg/mL)
  • Preferred regimen (1): (Penicillin G 24 million U/24h IV either continuously or q4–6h for 4 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 4 weeks) AND Gentamicin 3 mg/kg/24h IV/IM in 1 dose for 2 weeks
  • Preferred regimen (2): Vancomycin 30 mg/kg/24h IV q12h not to exceed 2 g/24h for 4 weeks
  • Pediatric dose: Penicillin G 200,000 U/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM in 1 dose; Gentamicin 3 mg/kg/24h IV/IM in 1 dose or q8h; Vancomycin 40 mg/kg/24h IV q8–12h
  • Prosthetic valve endocarditis caused by highly penicillin-susceptible viridans group streptococci and Streptococcus bovis (MIC ≤ 0.12 μg/mL)
  • Preferred regimen (1): (Penicillin G 24 million U/24h IV either continuously or q4–6h for 6 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 6 weeks) ± Gentamicin 3 mg/kg/24h IV/IM in 1 dose for 2 weeks
  • Preferred regimen (2): Vancomycin 30 mg/kg/24h IV q12h not to exceed 2 g/24h for 6 weeks
  • Pediatric dose: Penicillin G 200,000 U/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM in 1 dose; Gentamicin 3 mg/kg/24h IV/IM in 1 dose or q8h; Vancomycin 40 mg/kg/24h IV q8–12h
  • Prosthetic valve endocarditis caused by relatively penicillin-resistant viridans group streptococci and Streptococcus bovis (MIC > 0.12 μg/mL)
  • Preferred regimen (1): (Penicillin G 24 million U/24h IV either continuously or q4–6h for 6 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 6 weeks) AND Gentamicin 3 mg/kg/24h IV/IM in 1 dose for 2 weeks
  • Preferred regimen (2): Vancomycin 30 mg/kg/24h IV q12h not to exceed 2 g/24h for 6 weeks
  • Pediatric dose: Penicillin G 200,000 U/kg/24h IV q4–6h; Ceftriaxone 100 mg/kg/24h IV/IM in 1 dose; Gentamicin 3 mg/kg/24h IV/IM in 1 dose or q8h; Vancomycin 40 mg/kg/24h IV q8–12h

Intravascular catheter-related infections ⇧ Return to Top ⇧

Mediastinitis, acute ⇧ Return to Top ⇧

Mycotic aneurysm ⇧ Return to Top ⇧

  • Empiric antimicrobial therapy[2]

Myocarditis

Lyme carditis ⇧ Return to Top ⇧

  • Lyme carditis, adult[3]
  • Parenteral regimen
  • Preferred regimen: Ceftriaxone 2 g IV q24h for 14 (14–21) days
  • Alternative regimen: Cefotaxime 2 g IV q8h for 14 (14–21) days OR Penicillin G 18–24 million U/day IV q4h for 14 (14–21) days
  • Oral regimen
  • Preferred regimen: Amoxicillin 500 mg tid for 14 (14–21) days OR Doxycycline 100 mg bid for 14 (14–21) days OR Cefuroxime 500 mg bid for 14 (14–21) days
  • Alternative regimen: Azithromycin 500 mg PO qd for 7–10 days OR Clarithromycin 500 mg PO bid for 14–21 days (if the patient is not pregnant) OR Erythromycin 500 mg PO qid for 14–21 days
Note (1): Parenteral regimen is recommended at the start of therapy for patients who have been hospitalized for cardiac monitoring; oral regimen may be substituted to complete a course of therapy or to treat ambulatory patients.
Note (2): A temporary pacemaker may be required for patients with advanced heart block.
Note (3): Patients treated with macrolides should be closely observed to ensure resolution of the clinical manifestations.
  • Lyme carditis, pediatric[4]
  • Parenteral regimen
  • Preferred regimen: Ceftriaxone 50–75 mg/kg IV q24h (maximum, 2 g) for 14 (14–21) days
  • Alternative regimen: Cefotaxime 150–200 mg/kg/day IV q6–8h (maximum, 6 g per day) for 14 (14–21) days OR Penicillin G 200,000–400,000 U/kg/day IV q4h (not to exceed 18–24 million U per day) for 14 (14–21) days
  • Oral regimen
  • Preferred regimen: Amoxicillin 50 mg/kg/day PO tid (maximum, 500 mg per dose) for 14 (14–21) days OR Doxycycline (for children aged ≥ 􏱢8 years) 4 mg/kg/day PO bid (maximum, 100 mg per dose) for 14 (14–21) days OR Cefuroxime 30 mg/kg/day PO bid (maximum, 500 mg per dose) for 14 (14–21) days
  • Alternative regimen: Azithromycin 10 mg/kg/day (maximum of 500 mg per day) for 7–10 days OR Clarithromycin 7.5 mg/kg PO bid (maximum of 500 mg per dose) for 14–21 days OR Erythromycin 12.5 mg/kg PO qid (maximum of 500 mg per dose) for 14–21 days
Note (1): Parenteral regimen is recommended at the start of therapy for patients who have been hospitalized for cardiac monitoring; oral regimen may be substituted to complete a course of therapy or to treat ambulatory patients.
Note (2): A temporary pacemaker may be required for patients with advanced heart block.
Note (3): Patients treated with macrolides should be closely observed to ensure resolution of the clinical manifestations.

Myocarditis, viral ⇧ Return to Top ⇧

Pericarditis

Pericarditis, bacterial ⇧ Return to Top ⇧

  • Bacterial pericarditis
  • Empiric antimicrobial therapy[5][6]
  • Preferred regimen: Vancomycin 1 g IV q12h targeting trough levels of 15–20 μg/mL for 28 days AND Ciprofloxacin 400 mg IV q12h for 28 days
  • Alternative regimen (1): Vancomycin 1 g IV q12h targeting trough levels of 15–20 μg/mL for 28 days AND Cefepime 2 g IV q12h for 28 days
  • Alternative regimen (2): Vancomycin 1 g IV q12h targeting trough levels of 15–20 μg/mL for 14–42 days AND Ceftriaxone 2 g IV q24h for 14–42 days
Note: Pericardiocentesis must be promptly performed. Pericardial drainage combined with effective systemic antibiotic therapy is mandatory (antistaphylococcal agent plus aminoglycoside, followed by tailored antibiotic therapy according to cultures). Frequent irrigation of the pericardial cavity with urokinase or streptokinase may be considered. Open surgical drainage through subxiphoid pericardiotomy is preferable. Pericardiectomy may be required in patients with dense adhesions, loculated and thick purulent effusion, recurrence of tamponade, persistent infection, and progression to constriction.
  • Purulent pericarditis with contiguous pneumonia
  • Purulent pericarditis with contiguous head and neck infection
  • Purulent pericarditis secondary to infective endocarditis
  • Preferred regimen: Vancomycin 15–20 mg/kg IV q8–12h targeting trough levels of 15–20 μg/mL AND Gentamicin 3 mg/kg/day IV q8–12h
  • Purulent pericarditis after cardiac surgery, pediatric
  • Preferred regimen: Vancomycin 15 mg/kg IV q6h targeting trough levels of 15–20 μg/mL AND (Ceftriaxone 100 mg/kg/day IV q12–24h OR Cefotaxime 200–300 mg/kg/day IV q6–8h) AND Gentamicin 6–7.5 mg/kg/day IV q8h
  • Purulent pericarditis with genitourinary infection, pediatric
  • Preferred regimen: Vancomycin 15 mg/kg IV q6h targeting trough levels of 15–20 μg/mL AND (Ceftriaxone 100 mg/kg/day IV q12–24h OR Cefotaxime 200–300 mg/kg/day IV q6–8h) AND Gentamicin 6–7.5 mg/kg/day IV q8h
  • Purulent pericarditis in immunocompromised host, pediatric
  • Preferred regimen: Vancomycin 15 mg/kg IV q6h targeting trough levels of 15–20 μg/mL AND (Ceftriaxone 100 mg/kg/day IV q12–24h OR Cefotaxime 200–300 mg/kg/day IV q6–8h) AND Gentamicin 6–7.5 mg/kg/day IV q8h
  • Pathogen-directed antimicrobial therapy[11]
  • Anaerobes
  • Gram-negative bacilli
  • Legionella pneumophila
  • Mycoplasma pneumoniae
  • Neisseria meningitidis
  • Preferred regimen: Penicillin G 5–24 MU/day IM/IV q4–6h for 14–42 days OR Cefotaxime 2 g IV q6–8h for 14–42 days OR Ceftriaxone 2 g IV q24h for 14–42 days
  • Staphylococcus aureus, methicillin-susceptible
  • Preferred regimen: Nafcillin 1–2 g IV q4h for 14–42 days OR Oxacillin 1–2 g IV q4h for 14–42 days OR Cefazolin 1–2 g IV q48h for 14–42 days OR Vancomycin 1 g IV q12h targeting trough levels of 15–20 μg/mL for 14–42 days OR Clindamycin 600–900 mg IV q8h for 14–42 days
  • Staphylococcus aureus, methicillin-resistant
  • Preferred regimen: Vancomycin 1 g IV q12h targeting trough levels of 15–20 μg/mL for 14–42 days OR Linezolid 600 mg IV q12h for 14–42 days
  • Streptococcus pneumoniae, penicillin-susceptible
  • Streptococcus pneumoniae, penicillin-resistant
  • Preferred regimen: Ciprofloxacin 400 mg IV q12h for 14–42 days OR Levofloxacin 500–750 mg IV q24h for 14–42 days OR Vancomycin 1 g IV q12h targeting trough levels of 15–20 μg/mL for 14–42 days

Pericarditis, fungal ⇧ Return to Top ⇧

Pericarditis, tuberculous ⇧ Return to Top ⇧

Pericarditis, viral ⇧ Return to Top ⇧

Rheumatic fever

Rheumatic fever, primary prophylaxis ⇧ Return to Top ⇧

Rheumatic fever, secondary prophylaxis ⇧ Return to Top ⇧

Septic pelvic vein thrombophlebitis ⇧ Return to Top ⇧


Central Nervous System

Brain abscess ⇧ Return to Top ⇧

Cerebrospinal fluid shunt infection ⇧ Return to Top ⇧

Encephalitis ⇧ Return to Top ⇧

Epidural abscess ⇧ Return to Top ⇧

Lyme neuroborreliosis ⇧ Return to Top ⇧

Meningitis, bacterial ⇧ Return to Top ⇧

Meningitis, MRSA ⇧ Return to Top ⇧

Meningitis, tuberculous ⇧ Return to Top ⇧

Septic thrombosis of cavernous or dural venous sinus ⇧ Return to Top ⇧

Septic thrombosis of cavernous or dural venous sinus, MRSA ⇧ Return to Top ⇧

Subdural empyema ⇧ Return to Top ⇧


Head and Neck

Anthrax, oropharyngeal ⇧ Return to Top ⇧

Buccal cellulitis ⇧ Return to Top ⇧

Cervico-facial actinomycosis ⇧ Return to Top ⇧

Deep neck infection ⇧ Return to Top ⇧

Facial cellulitis ⇧ Return to Top ⇧

Mastoiditis ⇧ Return to Top ⇧

Mastoiditis, Acute ⇧ Return to Top ⇧

Mastoiditis, Chronic ⇧ Return to Top ⇧

Odontogenic infection ⇧ Return to Top ⇧

Orbital cellulitis ⇧ Return to Top ⇧

Oropharyngeal candidiasis ⇧ Return to Top ⇧

Otitis externa ⇧ Return to Top ⇧

Otitis externa, Chronic ⇧ Return to Top ⇧

Otitis externa, Fungal ⇧ Return to Top ⇧

Otitis externa, Malignant ⇧ Return to Top ⇧

Otitis externa, Swimmer's ear ⇧ Return to Top ⇧

Otitis media ⇧ Return to Top ⇧

Otitis media, Acute ⇧ Return to Top ⇧

Otitis media, Post-intubation ⇧ Return to Top ⇧

Otitis media, Prophylaxis ⇧ Return to Top ⇧

Otitis media, Treatment failure ⇧ Return to Top ⇧

Parotitis ⇧ Return to Top ⇧


Eye

Conjunctivitis ⇧ Return to Top ⇧

Blepharitis ⇧ Return to Top ⇧

Endophthalmitis, bacterial ⇧ Return to Top ⇧

Endophthalmitis, bleb-related ⇧ Return to Top ⇧

Endophthalmitis, candidal ⇧ Return to Top ⇧

Endophthalmitis, chronic ⇧ Return to Top ⇧

Endophthalmitis, mold ⇧ Return to Top ⇧

Endophthalmitis, post-cataract surgery, acute ⇧ Return to Top ⇧

Endophthalmitis, post-cataract surgery, chronic ⇧ Return to Top ⇧

Endophthalmitis, post-tramatic ⇧ Return to Top ⇧

Keratitis, bacterial ⇧ Return to Top ⇧

Keratitis, fungal ⇧ Return to Top ⇧

Keratitis, protozoal ⇧ Return to Top ⇧

Keratitis, viral ⇧ Return to Top ⇧

Ocular syphilis ⇧ Return to Top ⇧

Ocular toxocariasis ⇧ Return to Top ⇧

Ocular toxoplasmosis ⇧ Return to Top ⇧

Ocular tuberculosis ⇧ Return to Top ⇧

Orbital cellulitis ⇧ Return to Top ⇧

Periocular Infection ⇧ Return to Top ⇧

Retinal necrosis, acute, CMV ⇧ Return to Top ⇧

Retinal necrosis, acute, HSV or VZV ⇧ Return to Top ⇧

Retinal necrosis, progressive outer, VZV ⇧ Return to Top ⇧

Retinitis, CMV ⇧ Return to Top ⇧

Stye ⇧ Return to Top ⇧

Uveitis, acute anterior ⇧ Return to Top ⇧

Uveitis, Lyme disease ⇧ Return to Top ⇧


Upper Respiratory Tract

Epiglottitis ⇧ Return to Top ⇧

Jugular vein phlebitis ⇧ Return to Top ⇧

Laryngitis ⇧ Return to Top ⇧

Lemierre's syndrome ⇧ Return to Top ⇧

Ludwig's angina ⇧ Return to Top ⇧

Parapharyngeal space infection ⇧ Return to Top ⇧

Pharyngitis, diphtheria ⇧ Return to Top ⇧

Pharyngitis, streptococcal ⇧ Return to Top ⇧

Sinusitis, Acute ⇧ Return to Top ⇧

Sinusitis, Chronic ⇧ Return to Top ⇧

Sinusitis, Post-intubation ⇧ Return to Top ⇧

Sinusitis, Treatment failure ⇧ Return to Top ⇧

Stomatitis ⇧ Return to Top ⇧

Stomatitis, aphthous ⇧ Return to Top ⇧

Stomatitis, herpetic ⇧ Return to Top ⇧

Submandibular space infection ⇧ Return to Top ⇧

Tonsillitis ⇧ Return to Top ⇧

Ulcerative gingivitis ⇧ Return to Top ⇧

Vincent's angina ⇧ Return to Top ⇧


Lower Respiratory Tract

Acute bacterial exacerbations of chronic bronchitis ⇧ Return to Top ⇧

Bronchiectasis ⇧ Return to Top ⇧

Bronchiolitis ⇧ Return to Top ⇧

Bronchitis ⇧ Return to Top ⇧

Cystic fibrosis ⇧ Return to Top ⇧

Empyema ⇧ Return to Top ⇧

Influenza ⇧ Return to Top ⇧

Inhalational anthrax, Prophylaxis ⇧ Return to Top ⇧

Inhalational anthrax, Treatment ⇧ Return to Top ⇧

Pertussis ⇧ Return to Top ⇧

Pneumonia, Acinetobacter ⇧ Return to Top ⇧

Pneumonia, Actinomycosis ⇧ Return to Top ⇧

Pneumonia, Anaerobes ⇧ Return to Top ⇧

Pneumonia, Aspiration pneumonia ⇧ Return to Top ⇧

Pneumonia, Chlamydophila ⇧ Return to Top ⇧

Pneumonia, community-acquired ⇧ Return to Top ⇧

Pneumonia, concomitant influenza ⇧ Return to Top ⇧

Pneumonia, Cytomegalovirus ⇧ Return to Top ⇧

Pneumonia, Haemophilus Influenza ⇧ Return to Top ⇧

Pneumonia, health care-associated ⇧ Return to Top ⇧

Pneumonia, hospital-acquired ⇧ Return to Top ⇧

Pneumonia, Klebsiella ⇧ Return to Top ⇧

Pneumonia, Legionella ⇧ Return to Top ⇧

Pneumonia, Lung abscess ⇧ Return to Top ⇧

Pneumonia, Meliodosis ⇧ Return to Top ⇧

Pneumonia, Moraxella catarrhalis ⇧ Return to Top ⇧

Pneumonia, Mycoplasma ⇧ Return to Top ⇧

Pneumonia, neutropenic patient ⇧ Return to Top ⇧

Pneumonia, Nocardia ⇧ Return to Top ⇧

Pneumonia, post-influenza ⇧ Return to Top ⇧

Pneumonia, Pseuodomonas ⇧ Return to Top ⇧

Pneumonia, Staphylococcus aureus ⇧ Return to Top ⇧

Pneumonia, Stenotrophomonas ⇧ Return to Top ⇧

Pneumonia, Streptococcus pneumoniae ⇧ Return to Top ⇧

Pneumonia, Tularemia ⇧ Return to Top ⇧

Pneumonia, Yersinia pestis ⇧ Return to Top ⇧


Gastrointestinal and Intraabdominal

Anthrax, gastrointestinal ⇧ Return to Top ⇧

Appendicitis ⇧ Return to Top ⇧

Biliary sepsis ⇧ Return to Top ⇧

Cholangitis ⇧ Return to Top ⇧

Cholecystitis ⇧ Return to Top ⇧

Diverticulitis ⇧ Return to Top ⇧

Esophagitis ⇧ Return to Top ⇧

Hepatic abscess ⇧ Return to Top ⇧

Hepatitis A ⇧ Return to Top ⇧

Hepatitis B ⇧ Return to Top ⇧

Hepatitis C ⇧ Return to Top ⇧

Hepatitis D ⇧ Return to Top ⇧

Hepatitis E ⇧ Return to Top ⇧

Infectious diarrhea ⇧ Return to Top ⇧

Leptospirosis ⇧ Return to Top ⇧

Pancreatitis ⇧ Return to Top ⇧

Peliosis hepatitis ⇧ Return to Top ⇧

Peptic ulcer disease ⇧ Return to Top ⇧

Peritonitis, secondary to bowel perforation ⇧ Return to Top ⇧

Peritonitis, secondary to dialysis ⇧ Return to Top ⇧

Peritonitis, secondary to ruptured appendix ⇧ Return to Top ⇧

Peritonitis, secondary to ruptured diverticula ⇧ Return to Top ⇧

Peritonitis, spontaneous bacterial ⇧ Return to Top ⇧

Post-transplant infected biloma ⇧ Return to Top ⇧

Splenic abscess ⇧ Return to Top ⇧

Tropical sprue ⇧ Return to Top ⇧

Typhlitis ⇧ Return to Top ⇧

Variceal bleeding, prophylaxis ⇧ Return to Top ⇧

Whipple's disease ⇧ Return to Top ⇧


Genitourinary

Asymptomatic bacteriuria ⇧ Return to Top ⇧

Bacterial vaginosis ⇧ Return to Top ⇧

Cervicitis ⇧ Return to Top ⇧

Chancroid ⇧ Return to Top ⇧

Chlamydial infections ⇧ Return to Top ⇧

Chorioamnionitis ⇧ Return to Top ⇧

Cystitis ⇧ Return to Top ⇧

Ectoparasitic infections ⇧ Return to Top ⇧

Epididymitis ⇧ Return to Top ⇧

Genital herpes ⇧ Return to Top ⇧

Gonococcal infections ⇧ Return to Top ⇧

Granuloma Inguinale ⇧ Return to Top ⇧

Human papillomavirus infection ⇧ Return to Top ⇧

Lymphogranuloma venereum ⇧ Return to Top ⇧

Pelvic inflammatory disease ⇧ Return to Top ⇧

Proctocolitis ⇧ Return to Top ⇧

Prostatitis, acute bacterial ⇧ Return to Top ⇧

Prostatitis, chronic bacterial ⇧ Return to Top ⇧

Pyelonephritis ⇧ Return to Top ⇧

Syphilis ⇧ Return to Top ⇧

Urethritis ⇧ Return to Top ⇧

Vulvovaginal candidiasis ⇧ Return to Top ⇧


Musculoskeletal

Bursitis ⇧ Return to Top ⇧

Osteomyelitis, candidal ⇧ Return to Top ⇧

Osteomyelitis, chronic ⇧ Return to Top ⇧

Osteomyelitis, contiguous with vascular insufficiency ⇧ Return to Top ⇧

Osteomyelitis, contiguous without vascular insufficiency ⇧ Return to Top ⇧

Osteomyelitis, diabetic foot ⇧ Return to Top ⇧

Osteomyelitis, foot bone ⇧ Return to Top ⇧

Osteomyelitis, foot puncture wound ⇧ Return to Top ⇧

Osteomyelitis, hematogenous ⇧ Return to Top ⇧

Osteomyelitis, hemoglobinopathy ⇧ Return to Top ⇧

Osteomyelitis, prosthetic joint infection ⇧ Return to Top ⇧

Osteomyelitis, spinal implant ⇧ Return to Top ⇧

Osteomyelitis, sternal ⇧ Return to Top ⇧

Reactive arthritis, post-streptococcal arthritis ⇧ Return to Top ⇧

Reactive arthritis, Reiter's syndrome ⇧ Return to Top ⇧

Septic arthritis, brucellosis ⇧ Return to Top ⇧

Septic arthritis, candidal ⇧ Return to Top ⇧

Septic arthritis, gonococcal ⇧ Return to Top ⇧

Septic arthritis, Gram-negative bacilli ⇧ Return to Top ⇧

Septic arthritis, Histoplasmosis ⇧ Return to Top ⇧

Septic arthritis, Lyme disease ⇧ Return to Top ⇧

Septic arthritis, Mycobacterium tuberculosis ⇧ Return to Top ⇧

Septic arthritis, pneumococcal ⇧ Return to Top ⇧

Septic arthritis, post-intraarticular injection ⇧ Return to Top ⇧

Septic arthritis, staphylococcal ⇧ Return to Top ⇧

Septic arthritis, streptococcal ⇧ Return to Top ⇧


Skin and Soft Tissues

Acne vulgaris ⇧ Return to Top ⇧

Acne rosacea ⇧ Return to Top ⇧

Anthrax, cutaneous ⇧ Return to Top ⇧

Bacillary angiomatosis ⇧ Return to Top ⇧

Bite wounds ⇧ Return to Top ⇧

Bubonic plague ⇧ Return to Top ⇧

Carbuncle ⇧ Return to Top ⇧

Cat scratch disease ⇧ Return to Top ⇧

Cellulitis ⇧ Return to Top ⇧

Ecthyma ⇧ Return to Top ⇧

Erysipelas ⇧ Return to Top ⇧

Erysipeloid ⇧ Return to Top ⇧

Erythrasma ⇧ Return to Top ⇧

Fournier gangrene ⇧ Return to Top ⇧

Furuncle ⇧ Return to Top ⇧

Gas gangrene ⇧ Return to Top ⇧

Glanders ⇧ Return to Top ⇧

Impetigo ⇧ Return to Top ⇧

Lyme disease, cutaneous ⇧ Return to Top ⇧

Mastitis ⇧ Return to Top ⇧

Necrotizing fasciitis ⇧ Return to Top ⇧

Pilonidal cyst ⇧ Return to Top ⇧

Pyomyositis ⇧ Return to Top ⇧

Seborrheic dermatitis ⇧ Return to Top ⇧

Skin and soft tissue infection in neutropenic fever ⇧ Return to Top ⇧

Skin and soft tissue infection in cellular immunodeficiency ⇧ Return to Top ⇧

Surgical site infection ⇧ Return to Top ⇧

Tularemia ⇧ Return to Top ⇧

Vascular insufficieny ulcer ⇧ Return to Top ⇧

Vibrio infection ⇧ Return to Top ⇧

Wound infection ⇧ Return to Top ⇧

Yaws ⇧ Return to Top ⇧


Systemic

Anaplasmosis ⇧ Return to Top ⇧

Babesiosis ⇧ Return to Top ⇧

Bartonella ⇧ Return to Top ⇧

Botulism ⇧ Return to Top ⇧

Boutonneuese fever ⇧ Return to Top ⇧

Brucellosis ⇧ Return to Top ⇧

Diptheria ⇧ Return to Top ⇧

Ehrlichiolsis ⇧ Return to Top ⇧

Febrile neutropenia, prophylaxis ⇧ Return to Top ⇧

Febrile neutropenia, treatment ⇧ Return to Top ⇧

Kawasaki syndrome ⇧ Return to Top ⇧

Leptospirosis ⇧ Return to Top ⇧

Lymphadenitis ⇧ Return to Top ⇧

Lymphangitis ⇧ Return to Top ⇧

Relapsing fever ⇧ Return to Top ⇧

Rocky Mountain spotted fever ⇧ Return to Top ⇧

Salmonella bacteremia ⇧ Return to Top ⇧

Sepsis ⇧ Return to Top ⇧

Staphylococcal toxic shock syndrome ⇧ Return to Top ⇧

Streptococcal toxic shock syndrome ⇧ Return to Top ⇧

Tetanus ⇧ Return to Top ⇧

Tularemia ⇧ Return to Top ⇧

Typhoid fever ⇧ Return to Top ⇧

Typhus, louse-borne ⇧ Return to Top ⇧

Typhus, murine ⇧ Return to Top ⇧

Typhus, scrub ⇧ Return to Top ⇧


References

  1. ↑ Baddour, Larry M.; Wilson, Walter R.; Bayer, Arnold S.; Fowler, Vance G.; Bolger, Ann F.; Levison, Matthew E.; Ferrieri, Patricia; Gerber, Michael A.; Tani, Lloyd Y.; Gewitz, Michael H.; Tong, David C.; Steckelberg, James M.; Baltimore, Robert S.; Shulman, Stanford T.; Burns, Jane C.; Falace, Donald A.; Newburger, Jane W.; Pallasch, Thomas J.; Takahashi, Masato; Taubert, Kathryn A.; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America (2005-06-14). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): –394-434. doi:10.1161/CIRCULATIONAHA.105.165564. ISSN 1524-4539. PMID 15956145.
  2. ↑ Gilbert, David (2014). The Sanford guide to antimicrobial therapy 2014. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808782.
  3. ↑ Wormser, Gary P.; Dattwyler, Raymond J.; Shapiro, Eugene D.; Halperin, John J.; Steere, Allen C.; Klempner, Mark S.; Krause, Peter J.; Bakken, Johan S.; Strle, Franc; Stanek, Gerold; Bockenstedt, Linda; Fish, Durland; Dumler, J. Stephen; Nadelman, Robert B. (2006-11-01). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 43 (9): 1089–1134. doi:10.1086/508667. ISSN 1537-6591. PMID 17029130.
  4. ↑ Wormser, Gary P.; Dattwyler, Raymond J.; Shapiro, Eugene D.; Halperin, John J.; Steere, Allen C.; Klempner, Mark S.; Krause, Peter J.; Bakken, Johan S.; Strle, Franc; Stanek, Gerold; Bockenstedt, Linda; Fish, Durland; Dumler, J. Stephen; Nadelman, Robert B. (2006-11-01). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 43 (9): 1089–1134. doi:10.1086/508667. ISSN 1537-6591. PMID 17029130.
  5. ↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  6. ↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
  7. ↑ Maisch, Bernhard; Seferović, Petar M.; Ristić, Arsen D.; Erbel, Raimund; Rienmüller, Reiner; Adler, Yehuda; Tomkowski, Witold Z.; Thiene, Gaetano; Yacoub, Magdi H.; Task Force on the Diagnosis and Management of Pricardial Diseases of the European Society of Cardiology (2004-04). "Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology". European Heart Journal. 25 (7): 587–610. doi:10.1016/j.ehj.2004.02.002. ISSN 0195-668X. PMID 15120056. Check date values in: |date= (help)
  8. ↑ Pankuweit, Sabine; Ristić, Arsen D.; Seferović, Petar M.; Maisch, Bernhard (2005). "Bacterial pericarditis: diagnosis and management". American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions. 5 (2): 103–112. ISSN 1175-3277. PMID 15725041.
  9. ↑ Goodman, null (2000-08). "Purulent Pericarditis". Current Treatment Options in Cardiovascular Medicine. 2 (4): 343–350. ISSN 1092-8464. PMID 11096539. Check date values in: |date= (help)
  10. ↑ Cherry, James (2014). Feigin and Cherry's textbook of pediatric infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455711772.
  11. ↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
Retrieved from "https://www.wikidoc.org/index.php?title=Infectious_Disease_Project_Organ-Based_Infections&oldid=1104798"